2020-sample/1034604_2_0001209191-20-036702.txt:        <footnote id="F1">The option vests and becomes exercisable in full on the earlier to occur of June 11, 2021, or the date immediately prior to the date of the 2021 annual meeting of the Issuer's shareholders.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F1">This sale from the Walton Family Holdings Trust (the &quot;Trust&quot;) was executed in multiple trades at prices ranging from $149.39 to $150.39, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F2">This sale from the Trust was executed in multiple trades at prices ranging from $150.40 to $151.40, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F3">On November 24, 2020, the reporting person made a charitable gift of 650,000 shares of Common Stock.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F4">This sale from the Trust was executed in multiple trades at prices ranging from $151.815 to $151.97, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F5">The reporting person is a trustee of the Trust, the entity that holds 387,242,468 shares of Common Stock.  The reporting person disclaims beneficial ownership of the reported securities held by the Trust except to the extent of her pecuniary interest therein.</footnote>
2020-sample/104169_4_0001127602-20-030022.txt:        <footnote id="F6">The reporting person is a member of Walton Enterprises, LLC, the entity that owns 1,000,891,131 shares of Common Stock.  The reporting person disclaims beneficial ownership of the reported securities held by such LLC except to the extent of her pecuniary interest therein.</footnote>
2020-sample/1049521_1_0001562180-20-002168.txt:        <footnote id="F1">Pursuant to a 10b5-1 stock trading plan established on January 31, 2020.</footnote>
2020-sample/1049521_1_0001562180-20-002168.txt:        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.16, inclusive.</footnote>
2020-sample/1049521_1_0001562180-20-002168.txt:        <footnote id="F3">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.26 to $79.48 inclusive.</footnote>
2020-sample/1058725_3_0001712184-20-000269.txt:        <footnote id="F1">The rights offering is subject to termination or extension by the Issuer at any time prior to consummation.</footnote>
2020-sample/1058725_3_0001712184-20-000269.txt:        <footnote id="F2">The rights offering commenced on September 11, 2020.</footnote>
2020-sample/1058725_3_0001712184-20-000269.txt:        <footnote id="F3">The rights offering will expire at 5:00 p.m., New York City time, on September 25, 2020 unless extended by the Issuer.</footnote>
2020-sample/1084991_2_0001084991-20-000022.txt:        <footnote id="F1">The acquisition reflects an award of Restricted Stock pursuant to the Company's 2019 Equity Incentive Plan. The award vests in one-third annual increments beginning on the first anniversary of the grant date, subject to accelerated vesting under certain circumstances.</footnote>
2020-sample/1084991_2_0001084991-20-000022.txt:        <footnote id="F2">Not Applicable. The acquisition reflects an award of Restricted Stock Units (&quot;RSU&quot;) pursuant to the Company's 2019 Equity Incentive Plan. Each RSU represents the right to receive one share of Company common stock upon vesting.  The award vests in one-third annual increments beginning on the first anniversary of the grant date, subject to accelerated vesting under certain circumstances.</footnote>
2020-sample/1109354_3_0001179110-20-009902.txt:        <footnote id="F1">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.</footnote>
2020-sample/1109354_3_0001179110-20-009902.txt:        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.79, inclusive. The reporting person undertakes to provide to Bruker Corporation, any security holder of Bruker Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
2020-sample/1109354_3_0001179110-20-009902.txt:        <footnote id="F3">The option vested in three approximately equal annual installments on May 20, 2017, 2018 and 2019.</footnote>
2020-sample/1136554_4_0001209191-20-061181.txt:        <footnote id="F1">Price reflects a weighted average sale price for multiple transactions ranging from $193.75 to $193.8033 per share, inclusive.  The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.</footnote>
2020-sample/1136554_4_0001209191-20-061181.txt:        <footnote id="F2">This option is part of an option to purchase 3,121 STERIS ordinary shares, which is fully vested, which was received in conjunction with the Redomiciliation of the entity organized under the laws of the U.K. and formerly named STERIS plc (&quot;Old STERIS&quot;) in exchange for an option to purchase 3,121 Old STERIS ordinary shares for $31.61 per share, subject to the same terms and conditions as the original Old STERIS stock option, except as otherwise required by law.</footnote>
2020-sample/1158369_2_0001567619-20-011536.txt:        <footnote id="F1">Includes 15,845 restricted stock units that were reflected in reporting person's Form 4 filed on December 16, 2019.</footnote>
2020-sample/1192933_2_0001179110-20-005642.txt:        <footnote id="F1">The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full.</footnote>
2020-sample/1221787_2_0001209191-20-035900.txt:        <footnote id="F1">RSU deferred dividend reinvestment accrual.</footnote>
2020-sample/1221787_2_0001209191-20-035900.txt:        <footnote id="F2">Phantom Stock Units arising out of the Reporting Person's election to defer receipt of retainer fees.</footnote>
2020-sample/1221787_2_0001209191-20-035900.txt:        <footnote id="F3">The security converts to common stock on a one-for-one basis.</footnote>
2020-sample/1221787_2_0001209191-20-035900.txt:        <footnote id="F4">These units are to be settled in cash after the Reporting Person's retirement.</footnote>
2020-sample/1221787_2_0001209191-20-035900.txt:        <footnote id="F5">Dividend Equivalents accrued on exempt grant of unvested RSUs, which will vest and settle with the underlying award.</footnote>
2020-sample/1222848_4_0000746598-20-000179.txt:        <footnote id="F1">Reporting owner acquired 2,731 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors.  Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account.</footnote>
2020-sample/1227500_1_0000899243-20-004098.txt:        <footnote id="F1">Represents the grant of restricted stock units.  These restricted stock units vest in three equal annual installments beginning on February 7, 2021.</footnote>
2020-sample/1227500_1_0000899243-20-004098.txt:        <footnote id="F2">Includes 500 shares purchased on August 14, 2019 pursuant to the Equity Bancshares, Inc. 2019 Employee Stock Purchase Plan.</footnote>
2020-sample/1286331_1_0001286331-20-000001.txt:        <footnote id="F1">Exercisable, cumulatively, at 20% per year commencing February 12, 2020.</footnote>
2020-sample/1333986_1_0001209191-20-017244.txt:        <footnote id="F1">Includes restricted stock units.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F1">Shares of common stock (&quot;Common Stock&quot;) of Alexion Pharmaceuticals, Inc. (the &quot;Issuer&quot;) directly held by Felix J. Baker.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F2">Common Stock directly held by Julian C. Baker.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F3">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F4">3,468 restricted stock units (each, an &quot;RSU'&quot;) payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (&quot;Grant Date&quot;) in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (&quot;Stock Incentive Plan&quot;).  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F5">Felix J. Baker serves on the Issuer's Board of Directors (the &quot;Board&quot;) as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the &quot;Adviser&quot;), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (&quot;667&quot;) and Baker Brothers Life Sciences, L.P. (&quot;Life Sciences&quot;, and together with 667, the &quot;Funds&quot;) each own an indirect proportionate pecuniary interest in the RSUs.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F6">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F7">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F8">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.</footnote>
2020-sample/1363364_2_0001638599-20-000500.txt:        <footnote id="F9">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (&quot;Synageva Board&quot;), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (&quot;Predecessor Board&quot;). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.</footnote>
2020-sample/1370450_1_0001179110-20-000668.txt:        <footnote id="F1">Represents shares of the Issuer's Common Stock withheld for tax withholding purposes in connection with the vesting of restricted stock on October 31, 2019, which restricted stock was granted on October 21, 2017.</footnote>
2020-sample/1370450_1_0001179110-20-000668.txt:        <footnote id="F2">Includes (i) 444 shares of restricted stock that vest on March 8, 2020, (ii) 444 shares of restricted stock that vest on October 31, 2020 and (iii) an aggregate of 1,164 shares of Common Stock purchased under the Amended and Restated Willdan Group, Inc. 2006 Employee Stock Purchase Plan, including 225 shares on December 31, 2016, 229 shares on June 30, 2017, 225 shares on December 31, 2017, 355 shares on June 30, 2018 and 130 shares on December 31, 2018.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F1">Each restricted stock unit is convertible into a share of common stock on a 1-for-1 basis. The restricted stock units vested in common stock on February 22, 2020.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F2">Shares withheld by the Company to satisfy tax withholding requirements.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F3">Each restricted stock unit is convertible into a share of common stock on a 1-for-1 basis.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F4">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on May 12, 2018, one-third of these restricted stock units vested on May 12, 2019 and the remaining one-third of these restricted stock units vest on May 12, 2020, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F5">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on March 2, 2019, one-third of these restricted stock units vest on March 2, 2020 and the remaining one-third of these restricted stock units vest on March 2, 2021, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F6">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on February 22, 2020, one-third of these restricted stock units vest on February 22, 2021 and the remaining one-third of these restricted stock units vest on February 22, 2022, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F7">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on May 12, 2020, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F8">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on March 2, 2021, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1395942_1_0001395942-20-000033.txt:        <footnote id="F9">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on February 22, 2022, assuming continued employment through the applicable vesting date.</footnote>
2020-sample/1403161_2_0001127602-20-018860.txt:        <footnote id="F1">The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $197.0000-$197.3500, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities &amp; Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4.</footnote>
2020-sample/1403679_2_0001179110-20-006906.txt:        <footnote id="F1">Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.</footnote>
2020-sample/1403679_2_0001179110-20-006906.txt:        <footnote id="F2">Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.</footnote>
2020-sample/1412408_1_0000899243-20-001780.txt:        <footnote id="F1">The shares reported in this transaction represent Restricted Stock Units (&quot;RSUs&quot;) issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 10% of the RSUs shall vest on January 15, 2021, 20% of the RSUs shall vest on January 15, 2022, 30% of the RSUs shall vest on January 15, 2023 and 40% of the RSUs shall vest on January 15, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date.</footnote>
2020-sample/1412408_1_0000899243-20-001780.txt:        <footnote id="F2">These shares are subject to a Lock-Up Agreement until January 26, 2020.</footnote>
2020-sample/1412408_1_0000899243-20-001780.txt:        <footnote id="F3">A portion of these shares represent RSUs.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F1">Each share of Class B Common Stock is convertible without payment or consideration into one share of Class A Common Stock at the option of the holder and has no expiration date.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F2">These shares are held by Accel X L.P.  Accel X Associates L.L.C. (&quot;Accel X GP&quot;) is the general partner of each of Accel X L.P. and Accel X Strategic Partners L.P. (together, the &quot;Accel X Entities&quot;). Accel X GP has sole voting and dispositive power with regard to the shares held by the Accel X Entities. Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F3">On January 13, 2020, Accel X L.P. distributed, for no consideration, 4,931,850 shares of Class A common stock of the Issuer (the &quot;Accel X Shares&quot;) to its limited partners and to Accel X GP, the general partner of Accel X L.P., representing each such partner's pro rata interest in such Accel X Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Shares it received in the distribution by Accel X L.P. to its members, representing each such member's pro rata interest in such Accel X Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F4">These shares are held by Accel X Strategic Partners L.P.  Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F5">On January 13, 2020, Accel X Strategic Partners L.P. distributed, for no consideration, 370,150 shares of Class A common stock of the Issuer (the &quot;Accel X Strategic Shares&quot;) to its limited partners and to Accel X GP, the general partner of Accel X Strategic Partners L.P., representing each such partner's pro rata interest in such Accel X Strategic Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Strategic Shares it received in the distribution by the Fund to its members, representing each such member's pro rata interest in such Accel X Strategic Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F6">These shares are held by Accel Investors 2009 L.L.C.</footnote>
2020-sample/1430231_1_0000899243-20-001255.txt:        <footnote id="F7">On January 13, 2020, Accel Investors 2009 L.L.C. distributed, for no consideration, 198,000 shares of Class A common stock of the Issuer (the &quot;Accel 2009 Shares&quot;) to its members, representing each such member's pro rata interest in such Accel 2009 Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.</footnote>
2020-sample/1447887_1_0001393726-20-000022.txt:        <footnote id="F1">The Reporting Person was granted restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, pursuant to the Issuer's Equity Plan.  The restricted stock units will vest annually in three equal installments on each of February 15, 2021, 2022 and 2023 upon continuous employment from the grant date until such date, subject to certain terms contained in the Reporting Person's award agreement.</footnote>
2020-sample/1448238_1_0001357615-20-000104.txt:        <footnote id="F1">Represents shares withheld to pay withholding taxes due upon vestings.</footnote>
2020-sample/1467858_2_0001467858-20-000082.txt:        <footnote id="F1">The Restricted Stock Units (&quot;RSUs&quot;) reported in this item were awarded on May 7, 2020, pursuant to the Company's 2017 Long-Term Incentive Plan. The RSUs will vest on April 1, 2021.</footnote>
2020-sample/1467858_2_0001467858-20-000082.txt:        <footnote id="F2">Each RSU will be settled for one share of the Company's Common Stock.</footnote>
2020-sample/1474838_1_0001123292-20-000425.txt:        <footnote id="F1">These shares were issued to the reporting person pursuant to the Western New England Bancorp, Inc. 2017 Long-Term Incentive Plan, which provided for the award of shares of common stock of the Company based on the Company's performance over a designated three-year period.</footnote>
2020-sample/1474838_1_0001123292-20-000425.txt:        <footnote id="F2">Reflects shares of common stock surrendered to the Issuer to satisfy tax withholding obligations in connection with the award of common stock described in footnote 1.</footnote>
2020-sample/1478320_1_0001209191-20-009860.txt:        <footnote id="F1">The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.</footnote>
2020-sample/1480691_2_0001567619-20-008697.txt:        <footnote id="F1">Includes shares of restricted stock which vest at a rate of 20% per year commencing on December 19, 2019.</footnote>
2020-sample/1480691_2_0001567619-20-008697.txt:        <footnote id="F2">Stock options vest at a rate of 20% per year commencing on December 19, 2019.</footnote>
2020-sample/1484631_3_0001127602-20-025556.txt:        <footnote id="F1">Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on restricted stock units deferred under the Issuer's deferred compensation plan.</footnote>
2020-sample/1487371_1_0001487371-20-000092.txt:        <footnote id="F1">The price reported is the weighted average price per share.  Shares were purchased in multiple transactions at prices ranging from $4.60 to $4.62 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price.</footnote>
2020-sample/1491060_3_0001562180-20-006013.txt:        <footnote id="F1">Common stock acquired upon the lapse of Table II Restricted Stock Units based on the applicable Ball Corporation Stock and Cash Incentive Plan performance factor and in accordance with the provisions of said Plan.</footnote>
2020-sample/1491060_3_0001562180-20-006013.txt:        <footnote id="F2">Shares withheld for the payment of the tax obligation on the lapse of restrictions on Table II Performance Contingent Restricted Stock.</footnote>
2020-sample/1491060_3_0001562180-20-006013.txt:        <footnote id="F3">Total number of 401(k) Plan shares acquired through periodic dividend reinvestment, participant's contributions and employer matching contributions.</footnote>
2020-sample/1491060_3_0001562180-20-006013.txt:        <footnote id="F4">Each restricted stock unit represents a contingent right to receive one share of Ball Corporation Common Stock.</footnote>
2020-sample/1491060_3_0001562180-20-006013.txt:        <footnote id="F5">Lapse of restricted stock units.</footnote>
2020-sample/1501695_3_0000950123-20-007937.txt:        <footnote id="F1">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.</footnote>
2020-sample/1501695_3_0000950123-20-007937.txt:        <footnote id="F2">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.</footnote>
2020-sample/1505512_4_0001209191-20-061962.txt:        <footnote id="F1">Acquired from the Issuer pursuant to a Securities Purchase Agreement dated December 1, 2020 with a closing date of December 4, 2020.</footnote>
2020-sample/1509261_4_0001567619-20-017410.txt:        <footnote id="F1">The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2020.</footnote>
2020-sample/1509261_4_0001567619-20-017410.txt:        <footnote id="F2">The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.4299 to $0.44, inclusive.  The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).</footnote>
2020-sample/1509261_4_0001567619-20-017410.txt:        <footnote id="F3">The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.43 to $0.45, inclusive.  The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).</footnote>
2020-sample/1521439_1_0001225208-20-004137.txt:        <footnote id="F1">Represents shares withheld to cover taxes due upon the vesting of certain restricted stock awards.</footnote>
2020-sample/1529381_2_0000899243-20-012897.txt:        <footnote id="F1">Represents a grant of 20,242 restricted stock units pursuant to the Issuer's 2020 Amended and Restated Omnibus Performance Incentive Plan, all of which will vest on May 11, 2021.  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.</footnote>
2020-sample/1529381_2_0000899243-20-012897.txt:        <footnote id="F2">Of the 47,072 shares reported, 20,242 are unvested restricted stock units (including dividend equivalent rights) and 19,376 are vested deferred stock units (including dividend equivalent rights).</footnote>
2020-sample/1555280_4_0001555280-20-000303.txt:        <footnote id="F1">These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.</footnote>
2020-sample/1555280_4_0001555280-20-000303.txt:        <footnote id="F2">Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit).  Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.</footnote>
2020-sample/1564294_2_0001127602-20-014621.txt:        <footnote id="F1">The price reported is an average weighted price. These shares were sold in multiple transactions at prices ranging from $26.08 to $26.10, inclusive.  The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.</footnote>
2020-sample/1564294_2_0001127602-20-014621.txt:        <footnote id="F2">The price reported is an average weighted price. These shares were sold in multiple transactions at prices ranging from $26.12 to $26.155, inclusive.  The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.</footnote>
2020-sample/1564294_2_0001127602-20-014621.txt:        <footnote id="F3">Represents units of the PulteGroup, Inc. Stock Fund (the Fund) of the PulteGroup, Inc. 401(k) Plan.  The Fund consists of cash and Common Stock in amounts that vary from time to time.  The reporting person's units represent 2,990.679 shares of PulteGroup, Inc. Common Stock held in the Fund as of February 5, 2020.</footnote>
2020-sample/1576905_1_0001086222-20-000053.txt:        <footnote id="F1">Each restricted stock unit (&quot;RSU&quot;) represents the right to receive one share of Akamai common stock upon vesting.</footnote>
2020-sample/1576905_1_0001086222-20-000053.txt:        <footnote id="F2">RSU vests over three years as follows:  1/3 on each of March 1, 2020, 2021 and 2022.</footnote>
2020-sample/1609298_4_0001014100-20-000068.txt:        <footnote id="F1">The shares were purchased pursuant to a dividend reinvestment program offered through a brokerage account maintained by the reporting person.</footnote>
2020-sample/1626431_3_0001819285-20-000013.txt:        <footnote id="F1">Represents full vesting of shares earned under a performance stock award granted in September 2017 under the Microsoft Corporation Executive Incentive Plan for the 3-year performance period that ended on June 30, 2020.</footnote>
2020-sample/1632944_3_0001567619-20-015688.txt:        <footnote id="F1">Includes dividend equivalents accrued during the performance period that are subject to the same performance-based and time-based vesting conditions as the underlying stock-settled performance stock units.</footnote>
2020-sample/1632944_3_0001567619-20-015688.txt:        <footnote id="F2">The stock-settled performance stock units were deemed to have settled for an equivalent number of shares of News Corporation's Class A Common Stock.</footnote>
2020-sample/1632944_3_0001567619-20-015688.txt:        <footnote id="F3">Represents shares withheld upon vesting of stock-settled performance stock units to satisfy tax withholding obligation.</footnote>
2020-sample/1632944_3_0001567619-20-015688.txt:        <footnote id="F4">Each stock-settled performance stock unit is the economic equivalent of one share of News Corporation's Class A Common Stock.</footnote>
2020-sample/1637459_2_0001637459-20-000087.txt:        <footnote id="F1">Grant of deferred shares, receipt of which is deferred until the six-month anniversary of the reporting person's separation from service as a director of Kraft Heinz.</footnote>
2020-sample/1642376_2_0001140361-20-013703.txt:        <footnote id="F1">Collectively, the securities (the &quot;Common Shares&quot;) reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the &quot;US Funds&quot;) and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the &quot;Euro Funds&quot; and together with the US Funds, the &quot;Funds&quot;).</footnote>
2020-sample/1642376_2_0001140361-20-013703.txt:        <footnote id="F2">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.</footnote>
2020-sample/1642376_2_0001140361-20-013703.txt:        <footnote id="F3">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.</footnote>
2020-sample/1653558_4_0001747632-20-000021.txt:        <footnote id="F1">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-trading plan adopted by the Reporting Person.</footnote>
2020-sample/1653558_4_0001747632-20-000021.txt:        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.73 to $2.92, inclusive. The Reporting Person undertakes to provide to Priority Technology Holdings, Inc., any security holder of Priority Technology Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.</footnote>
2020-sample/1653558_4_0001747632-20-000021.txt:        <footnote id="F3">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.67 to $2.75, inclusive. The Reporting Person undertakes to provide to Priority Technology Holdings, Inc., any security holder of Priority Technology Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F1">Represents shares of Class A Common Stock acquired by The Lorenzo J. Fertitta and Teresa Jo Fertitta Family Trust (the &quot;L&amp;T Fertitta Family Trust&quot;), a revocable trust established for the benefit of Lorenzo J. Fertitta and Teresa Jo Fertitta and for which Lorenzo J. Fertitta is co-trustee and has shared investment and voting power.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F2">Represents shares of Class A Common Stock acquired by the Frank J. Fertitta, III 2006 Irrevocable Trust (the &quot;FJF Irrevocable Trust&quot;), an irrevocable trust established for the benefit of Frank J. Fertitta III's three children and for which Lorenzo J. Fertitta is trustee and has sole investment and voting power.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F3">Represents a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $16.375 to $16.475.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F4">Lorenzo J. Fertitta is a director of the Issuer, and also a beneficial owner of 10% or more of the Issuer's Class A Common Stock (assuming that all of the units of membership interest in Station Holdco LLC (the &quot;LLC Units&quot;) beneficially owned by Lorenzo J. Fertitta were exchanged for the Issuer's Class A Common Stock) as a result of his ownership interest in FBM Sub 1 LLC (&quot;FBM Sub 1&quot;), Fertitta Business Management LLC (&quot;FBM&quot;) and FI Station Investor LLC (&quot;FI Station&quot;).  The LLC Units are exchangeable at any time and from time to time for an equal number of shares of the Issuer's Class A Common Stock or, at the election of the Issuer, cash.  The LLC Units have no expiration date.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F5">FI Station is owned by Fertitta Investment LLC (&quot;Fertitta Investment&quot;), KVF Investments, LLC (&quot;KVF&quot;) and LNA Investments, LLC (&quot;LNA&quot;).  Fertitta Investment is owned by FBM, KVF and LNA.  FI Station and Fertitta Investment are managed by Fertitta Holdco LLC, which is owned and managed by Frank J. Fertitta III and Lorenzo J. Fertitta.  KVF is managed by Frank J. Fertitta III and is beneficially owned by various trusts established for the benefit of his three children.  LNA is managed by Lorenzo J. Fertitta and is beneficially owned by various trusts established for the benefit of his three children.  FBM Sub 1 is owned and controlled by FBM.  FBM is owned and controlled (i) 50% by the F &amp; J Fertitta Family Business Trust (the &quot;F&amp;J Trust&quot;), a revocable trust for which Frank J. Fertitta III has sole investment and voting power, and (ii) 50% by the L &amp; T Fertitta Family Business Trust (the &quot;L&amp;T Trust&quot;), a revocable trust for which Lorenzo J. Fertitta has sole investment and voting power.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F6">(continued from Footnote 5) Certain Class A Common Stock of the Issuer are held by (i) The Lorenzo J. Fertitta and Teresa Jo Fertitta Family Trust (the &quot;L&amp;T Fertitta Family Trust&quot;), a revocable trust established for the benefit of Lorenzo J. Fertitta and Teresa Jo Fertitta and for which Lorenzo J. Fertitta is co-trustee and has shared investment and voting power, (ii) the Frank J. Fertitta, III 2006 Irrevocable Trust (the &quot;FJF Irrevocable Trust&quot;), an irrevocable trust established for the benefit of Frank J. Fertitta III's three children and for which Lorenzo J. Fertitta is trustee and has sole investment and voting power and (iii) the L &amp; T Fertitta Grandchildren's 2020 Irrevocable Trust, an irrevocable trust established for the benefit of the Reporting Person's grandchildren (the &quot;L&amp;T 2020 Trust&quot;) for which Frank J. Fertitta IV, the Reporting Person's nephew, serves as trustee.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F7">(continued from Footnote 6) Based on the Reporting Person's retained right to remove the trustee of the L&amp;T 2020 Trust, the Reporting Person may be deemed to be a beneficial owner of the shares transferred to the L&amp;T 2020 Trust.</footnote>
2020-sample/1653653_3_0000899243-20-022914.txt:        <footnote id="F8">Lorenzo J. Fertitta disclaims beneficial ownership of any shares of Class A Common Stock or LLC Units beneficially owned by FI Station, Fertitta Investment, FBM Sub 1, FBM, KVF, LNA, the F&amp;J Trust, the L&amp;T Trust, the L&amp;T Fertitta Family Trust, the FJF Irrevocable Trust, and the L&amp;T 2020 Trust, except to the extent of any pecuniary interest therein.</footnote>
2020-sample/1655020_2_0001655020-20-000058.txt:        <footnote id="F1">These shares represent amounts withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations</footnote>
2020-sample/1655020_2_0001655020-20-000058.txt:        <footnote id="F2">These shares are owned by OFI Properties, LLC, of which Mr. Owens holds 100% of the managing interest. The Matthew R. Owens 2016 Grantor Retained Annuity Trust, of which Mr. Owens is Trustee, owns a 75% non-managing interest in OFI Properties, LLC.</footnote>
2020-sample/1656557_3_0001493152-20-018537.txt:        <footnote id="F1">The shares were withheld by the Issuer to cover withholding taxes resulting from vesting of restricted stock awards that were previously reported on Table I.</footnote>
2020-sample/1664232_3_0001474506-20-000267.txt:        <footnote id="F1">Shares were sold pursuant to a 10b5 plan dated June 15, 2020.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F1">These securities are held in the account of Edenbrook Long Only Value Fund, LP, a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manger of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F2">These securities are held in the account of a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manager of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F3">Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F4">As previously disclosed, Edenbrook Long Only Value Fund, LP wrote 2550, 2550 and 3050 put option contracts expiring in March 2020, June 2020 and September 2020, respectively, which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of  common stock at the stated strike price if the counterparty exercises such put options.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F5">As previously disclosed, a private fund managed by Edenbrook Capital, LLC wrote 450, 450 and 450 put option contracts expiring in  March 2020, June 2020 and September 2020, respectively, which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put options.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F6">As previously disclosed, Edenbrook Long Only Value Fund, LP  bought 425 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F7">As previously disclosed, a private fund managed by Edenbrook Capital, LLC  bought 75 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated price.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F8">Edenbrook Long Only Value Fund, LP wrote 2200 put option contracts expiring in December 2020 which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of common stock at the stated  strike price if the counterparty exercises such put option.</footnote>
2020-sample/1665975_1_0001062993-20-000814.txt:        <footnote id="F9">A private fund managed by Edenbrook Capital, LLC wrote 300 put option contracts expiring in December 2020 which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put option.</footnote>
2020-sample/1681459_1_0001681459-20-000017.txt:        <footnote id="F1">Represents the weighted average trading price (EUR 13.70) of the shares purchased on the Euronext Paris Exchange based on an exchange rate of EUR 1 to USD 1.1026 on the date of the transaction.  The trading range for these shares was EUR 13.50 to EUR 14.00.  The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Securities Exchange Commission, the Issuer, or a security holder of the Issuer.</footnote>
2020-sample/1686807_1_0000947871-20-000166.txt:        <footnote id="F1">Shares withheld upon vesting of restricted common stock awarded to reporting person pursuant to The Chefs' Warehouse 2019 Omnibus Equity Incentive Plan (the &quot;Plan&quot;).</footnote>
2020-sample/1686807_1_0000947871-20-000166.txt:        <footnote id="F2">The reporting person received 9,656 shares of restricted common stock pursuant to the Plan. The forfeiture restrictions associated with this award will lapse in one-third increments as of the first through third anniversary dates of the grant date, February 25, 2020.</footnote>
2020-sample/1692819_4_0001209191-20-054087.txt:        <footnote id="F1">This transaction represents the withholding by the Issuer of shares to pay taxes in connection with the vesting of restricted stock units. The timing and amount of the transaction were determined by the terms of the applicable restricted stock unit award and were not within the control of the Reporting Person.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F1">Restricted stock units (&quot;RSUs&quot;) convert into Class A Common Stock on a one-for-one basis.  This transaction represents the settlement of RSUs in shares of Class A Common Stock on their scheduled vesting date.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F2">Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale does not represent a discretionary trade by the reporting person.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F3">Represents the weighted average sale price for shares sold in multiple transactions. Sale prices ranged from $7.5550 to $7.5700 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F4">On February 26, 2020, the reporting person was granted 6,667 RSUs, scheduled to vest over four years in quarterly installments, with 6.25% of the RSUs vesting on each May 25, August 25, November 25 and February 25 over the four-year period following February 26, 2020.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F5">On May 25, 2020, the reporting person was granted 6,667 RSUs, scheduled to vest over four years in quarterly installments, with 6.25% of the RSUs vesting on each August 25, November 25, February 25 and May 25 over the four-year period following May 25, 2020.</footnote>
2020-sample/1701114_3_0001104659-20-099652.txt:        <footnote id="F6">On August 25, 2020, the reporting person was granted 6,667 RSUs, with 12.5% of the RSUs scheduled to vest on each of November 25, 2020 and February 25, 2021 and the remainder scheduled to vest thereafter in quarterly installments with 6.25% of the remainder vesting on each November 25, February 25, May 25 and August 25 thereafter over the four-year period beginning on May 25, 2021.</footnote>
2020-sample/1703752_3_0001567619-20-016232.txt:        <footnote id="F1">Includes shares of restricted stock which vest at a rate of 20% per year commencing on October 24, 2019.</footnote>
2020-sample/1703752_3_0001567619-20-016232.txt:        <footnote id="F2">Stock options vest at a rate of 20% per year commencing on October 24, 2019.</footnote>
2020-sample/1703752_3_0001567619-20-016232.txt:        <footnote id="F3">Each share of phantom stock is the economic equivalent of one share of common stock and becomes payable upon the reporting person's termination of service as a director.</footnote>
2020-sample/1715974_4_0001246360-20-001800.txt:        <footnote id="F1">OPTIONS VEST IN EQUAL INSTALLMENTS ON THE FIRST THREE ANNIVERSARIES OF THE GRANT DATE (11/5/2021, 11/5/2022 AND 11/5/2023).</footnote>
2020-sample/1715974_4_0001246360-20-001800.txt:        <footnote id="F2">RESTRICTED STOCK UNITS WILL VEST ANNUALLY IN EQUAL INSTALLMENTS ON THE FIRST THREE ANNIVERSARIES OF THE GRANT DATE AND CONVERT INTO COMMON STOCK ON A ONE-FOR-ONE-BASIS.</footnote>
2020-sample/1717452_3_0001209191-20-042779.txt:        <footnote id="F1">These shares were acquired on 07/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).</footnote>
2020-sample/1717452_3_0001209191-20-042779.txt:        <footnote id="F2">The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (&quot;FDA&quot;) approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.</footnote>
2020-sample/1721010_2_0001420506-20-000473.txt:        <footnote id="F1">Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock</footnote>
2020-sample/1729427_2_0001683168-20-001965.txt:        <footnote id="F1">The stock options set forth in this table vest on the earlier of the one-year anniversary of the issuance date or the date of the 2021 annual meeting, subject to the grantee's continued service to the Company on the vesting date.</footnote>
2020-sample/1729427_2_0001683168-20-001965.txt:        <footnote id="F2">The stock options were issued in connection with the reporting person's Board of Director services to the Company.</footnote>
2020-sample/1733121_3_0001179110-20-009502.txt:        <footnote id="F1">The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.60 to $9.70, inclusive. The reporting person undertakes to provide Bridgewater Bancshares, Inc., any security holder of Bridgewater Bancshares, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote to this Form 4.</footnote>
2020-sample/1733121_3_0001179110-20-009502.txt:        <footnote id="F2">Shares of common stock are held by Mr. Juran as co-trustee of a Marital Trust dated June 18, 2002. Mr. Juran possesses shared voting and investment power with respect to the shares of common stock held under the trust.</footnote>
2020-sample/1733121_3_0001179110-20-009502.txt:        <footnote id="F3">Shares of common stock are held by Mr. Juran as co-trustee of a Residuary Trust dated June 18, 2002. Mr. Juran possesses shared voting and investment power with respect to the shares of common stock held under the trust.</footnote>
2020-sample/1733285_3_0001179110-20-007871.txt:        <footnote id="F1">Shares of common stock are held by Mr. Johnson as co-trustee of the James S. Johnson Trust, dated May 28, 2015. Mr. Johnson possesses shared voting and investment power with respect to the shares of common stock held under the James S. Johnson Trust dated May 28, 2015.</footnote>
2020-sample/1733285_3_0001179110-20-007871.txt:        <footnote id="F2">Shares of common stock are held by Mr. Johnson as co-trustee of the Jolynn Johnson Trust dated May 28, 2015. Mr. Johnson possesses shared voting and investment power with respect to the shares of common stock held under the Jolynn Johnson Trust dated May 28, 2015.</footnote>
2020-sample/1737287_4_0001214659-20-008571.txt:        <footnote id="F1">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020.</footnote>
2020-sample/1737287_4_0001214659-20-008571.txt:        <footnote id="F2">One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter.</footnote>
2020-sample/1744027_1_0000899243-20-006522.txt:        <footnote id="F1">These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021.</footnote>
2020-sample/1760231_1_0001209191-20-013621.txt:        <footnote id="F1">The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.</footnote>
2020-sample/1760231_1_0001209191-20-013621.txt:        <footnote id="F3">Certain of these securities are restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.</footnote>
2020-sample/1760231_1_0001209191-20-013621.txt:        <footnote id="F4">This transaction was executed in multiple trades at prices ranging from $41.00 to $41.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.</footnote>
2020-sample/1763219_1_0000028412-20-000014.txt:        <footnote id="F1">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 24, 2020.</footnote>
2020-sample/1763219_1_0000028412-20-000014.txt:        <footnote id="F2">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 26, 2020.</footnote>
2020-sample/1763219_1_0000028412-20-000014.txt:        <footnote id="F3">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 27, 2020.</footnote>
2020-sample/1763219_1_0000028412-20-000014.txt:        <footnote id="F4">The options vest in four equal annual installments (based on the original grant amount) beginning on the date indicated in this column.</footnote>
2020-sample/1767760_2_0000899243-20-012336.txt:        <footnote id="F1">The reporting person elected to defer receipt of 1,865 shares of shares of common stock of the Company pursuant to the Terreno Realty Corporation Deferred Compensation Plan.</footnote>
2020-sample/1770686_2_0001209191-20-023848.txt:        <footnote id="F1">This prearranged sale was effected pursuant to a written authorization executed by the Reporting Person on September 11, 2019, and represents shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units.</footnote>
2020-sample/1780270_3_0001209191-20-042037.txt:        <footnote id="F1">The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.</footnote>
2020-sample/1780270_3_0001209191-20-042037.txt:        <footnote id="F2">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.42 to $26.28 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
2020-sample/1780270_3_0001209191-20-042037.txt:        <footnote id="F3">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.38 to $25.36 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
2020-sample/1780270_3_0001209191-20-042037.txt:        <footnote id="F4">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.54 to $26.11 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
2020-sample/1780270_3_0001209191-20-042037.txt:        <footnote id="F5">The option vests as to 2.0833% of the total shares monthly, beginning October 30, 2018, with 100% of the total shares vested and exercisable on September 30, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.</footnote>
2020-sample/1789635_3_0001140361-20-021384.txt:        <footnote id="F1">At the request of the holder, each Common Unit of One Water Marine Holdings, LLC (&quot;OneWater LLC&quot;)  may be coupled with a share of Class B common stock and redeemed for, at the Issuer's election and subject to certain restrictions in the Fourth Amended and Restated Limited Liability Company Agreement of OneWater LLC (the &quot;OneWater LLC Agreement&quot;), newly-issued shares of Class A common stock of OneWater Marine Inc. on a one-for-one basis or for a cash payment to be determined pursuant to the OneWater LLC Agreement for each Common Unit redeemed. The Common Units do not expire.</footnote>
2020-sample/1789635_3_0001140361-20-021384.txt:        <footnote id="F2">Pursuant to the OneWater LLC Agreement,  the shares of the Issuer's Class B common stock were cancelled for no consideration on a one-for-one basis upon the redemption by the Reporting Person of OneWater LLC common units, together with a corresponding number of shares of Class B common stock, for shares of the Issuer's Class A common stock.</footnote>
2020-sample/1791106_4_0000950103-20-020650.txt:        <footnote id="F1">Represents shares automatically withheld for payment of tax liability arising as a result of the partial settlement of restricted stock unit awards that vested.</footnote>
2020-sample/1792658_1_0001580695-20-000125.txt:        <footnote id="F1">Issued in consideration for service on the Board of Directors for a portion of the quarter ended February 29, 2020. Approved by the Compensation Committee and the Board of Directors, and granted under the registrant's 2017 Equity Incentive Plan, as amended. Exempt pursuant to Rule 16b3(d).</footnote>
2020-sample/1794684_2_0001567619-20-008161.txt:        <footnote id="F1">Common Stock Equivalents issued in lieu of cash dividends on the Common Stock Equivalents held by the director on the record date. Each Common Stock Equivalent is the economic equivalent of one share of common stock. The Common Stock Equivalents become payable in common stock upon, or at the election of the reporting person in installments beginning upon, the termination of the reporting person's service as a director or such earlier time as the director may  have designated.</footnote>
2020-sample/1796068_4_0001321732-20-000141.txt:        <footnote id="F1">Shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units granted to the Reporting Person.</footnote>
2020-sample/1796068_4_0001321732-20-000141.txt:        <footnote id="F2">A portion of these shares is subject to vesting.</footnote>
2020-sample/1796068_4_0001321732-20-000141.txt:        <footnote id="F3">Shares are held by the Reporting Person's spouse in an IRA.</footnote>
2020-sample/1797374_2_0001225208-20-008176.txt:        <footnote id="F1">Represents the vesting and share settlement of a performance share award approved by the Issuer on March 13, 2017. Performance for this award was measured based on the Issuer's total shareholder return (TSR) compared to the TSR of the companies within the S&amp;P 500 Index, over the 36-month period commencing on January 29, 2017, and ending on February 1, 2020. The performance results and number of shares earned based on the results were approved by the Compensation and Human Resources Committee of the Board of Directors on May 20, 2020.</footnote>
2020-sample/1801742_1_0001127602-20-005746.txt:        <footnote id="F1">The restricted stock units vest 50% on 2/11/22, 75% on 2/11/23 and 100% on 2/11/24.</footnote>
2020-sample/19411_1_0001209191-20-016902.txt:        <footnote id="F1">Not applicable.</footnote>
2020-sample/19411_1_0001209191-20-016902.txt:        <footnote id="F2">On the third anniversary of the grant date, Performance-Based Restricted Stock Units (&quot;PSUs&quot;) vest based on achievement of total shareholder return (&quot;TSR&quot;) performance relative to the S&amp;P Health Services Industry Index over a three-year period beginning in 2020 and ending in 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable.  The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number.</footnote>
2020-sample/19411_1_0001209191-20-016902.txt:        <footnote id="F3">(Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number.</footnote>
2020-sample/19411_1_0001209191-20-016902.txt:        <footnote id="F4">Restricted Stock Units vest in one third increments on March 4th of each of 2021, 2022 and 2023.</footnote>
2020-sample/21535_2_0001209191-20-031894.txt:        <footnote id="F1">The shares with respect to this transaction were sold in multiple trades at prices ranging from $15.190 to $15.525; the price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.</footnote>
2020-sample/21535_2_0001209191-20-031894.txt:        <footnote id="F2">Number of shares includes 8,532 Restricted Stock Units (RSUs) previously reported that in the future will be converted on a one-for-one basis into shares of Cohu, Inc. Common Stock immediately upon the vesting date (assuming continued service to the Board of Directors).</footnote>
2020-sample/23197_3_0000023197-20-000081.txt:        <footnote id="F1">Restricted stock awards were granted under the Company's 2000 Stock Incentive Plan, and represent the right to receive one share of common stock of Comtech Telecommunications Corp. upon vesting.</footnote>
2020-sample/23197_3_0000023197-20-000081.txt:        <footnote id="F2">Generally, the restricted stock awards will vest in installments over a five year period, at a rate of 20% on the first through fifth anniversaries of grant, assuming continued service as a director. Shares of common stock corresponding to vested awards will be delivered to the reporting person within 30 days of vesting.</footnote>
2020-sample/315054_2_0001140361-20-011342.txt:        <footnote id="F1">The price is a weighted average of the multiple trades that took place on 5/11/2020. The lowest price at which the shares were sold was $12.50 and the highest price was $12.685.</footnote>
2020-sample/354707_1_0000354707-20-000046.txt:        <footnote id="F1">Transfer of shares to Trust Account.</footnote>
2020-sample/354707_1_0000354707-20-000046.txt:        <footnote id="F2">Includes accrued dividend equivalents (as denominated in shares of HE common stock) from January 31, 2017 (first RSU grants in 2017) to date.  Dividend equivalents accrue in HE common stock with respect to outstanding RSUs when and as dividends are paid.  Accrued dividend equivalents are denominated in HE common stock and paid upon vesting in shares of HE common stock.</footnote>
2020-sample/354707_1_0000354707-20-000046.txt:        <footnote id="F3">Includes shares acquired under the Hawaiian Electric Industries, Inc. Dividend Reinvestment and Stock Purchase Plan.</footnote>
2020-sample/66570_4_0001225208-20-013358.txt:        <footnote id="F1">Share price on this transaction ranged from $143.68 to $143.93.</footnote>
2020-sample/66570_4_0001225208-20-013358.txt:        <footnote id="F2">Share price on this transaction ranged from $141.80 to $141.89.</footnote>
2020-sample/66570_4_0001225208-20-013358.txt:        <footnote id="F3">Share price on this transaction ranged from $142.00 to $142.85.</footnote>
2020-sample/732712_3_0001611593-20-000201.txt:        <footnote id="F1">Each share of phantom stock is the economic equivalent of a portion of one share of common stock and is settled in cash.  The shares of phantom stock become payable upon events established by the reporting person in accordance with the deferred compensation plan.</footnote>
2020-sample/732712_3_0001611593-20-000201.txt:        <footnote id="F2">Includes phantom stock acquired through dividend reinvestment.</footnote>
2020-sample/740260_1_0000740260-20-000022.txt:        <footnote id="F1">Represents shares withheld to pay taxes on the vesting of restricted stock units granted on January 18, 2017 under the Ventas, Inc. 2012 Incentive Plan (the &quot;Plan&quot;).  Such vested units are payable solely in common stock of the Issuer and subject to the terms of the Plan.</footnote>
2020-sample/740260_1_0000740260-20-000022.txt:        <footnote id="F2">As of January 18, 2020, Reporting Person owns options to purchase an aggregate of 346,140 shares of Issuer's common stock.</footnote>
2020-sample/748592_1_0001493152-20-000071.txt:        <footnote id="F1">This restricted stock grant was issued to the reporting person under the NTN Buzztime, Inc. 2019 Performance Incentive Plan and pursuant to the NTN Buzztime, Inc. Non-Employee Director Compensation Policy in lieu of the annual retainer earned by the reporting person in his capacity as a non-employee director of the issuer with respect to the quarter ended December 31, 2019. This restricted stock grant was fully-vested on the date of grant.</footnote>
2020-sample/748592_1_0001493152-20-000071.txt:        <footnote id="F2">Owned by minor child.</footnote>
2020-sample/793733_1_0001179110-20-001267.txt:        <footnote id="F1">Shares issued pursuant to the SkyWest, Inc. Long-Term Incentive Plan.</footnote>
2020-sample/897802_3_0001104659-20-084115.txt:        <footnote id="F1">The Reporting Person disclaims beneficial ownership of the securities owned by his spouse and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.</footnote>
2020-sample/899866_1_0000899866-20-000022.txt:        <footnote id="F1">Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date.</footnote>
2020-sample/912728_4_0000912728-20-000168.txt:        <footnote id="F1">This option vests 33-1/3% each year over a three year period commencing on 2/6/18.</footnote>
2020-sample/912728_4_0000912728-20-000168.txt:        <footnote id="F2">This option vests 33-1/3% each year over a three year period commencing on 2/5/19.</footnote>
